HK Stock Market Move | VENUS MEDTECH-B(02500) rose more than 7%. Mid-term clinical trial of Cardiovalve tricuspid valve replacement system shows good safety and efficacy.

VENUS MEDTECH-B (02500) rose more than 7%, as of the time of publication, it rose 7.02% to HK$2.44, with a turnover of HK$45.441 million. On the news side, on November 19, Venus Medtech announced the mid-term clinical results of the innovative transcatheter tricuspid valve replacement system Cardiovalve in the TARGET study. The TARGET study is a prospective, multicenter single-arm clinical trial, involving 25 centers in Germany, Spain, Italy, Canada, and the UK, with a total of 125 patients with an average age of 77. The study showed that the average procedure time was 5829 minutes, with an in-procedure success rate of 88%, and an implantation success rate of 95%. Follow-up at 6 months post-operation showed that 100% of patients had no moderate or severe regurgitation, 88% had improved heart function to grade I/II, which increased to 90% at 12 months, the average improvement in quality of life questionnaire scores was 20 points, and the 6-minute walk distance increased by 44 meters and 32 meters respectively. In terms of safety, the all-cause mortality rate was 6.4% (8/125), with a heart failure rehospitalization rate of 1.6%, and low rates of pericardial effusion, disabling stroke, and acute kidney injury requiring renal replacement therapy. Venus Medtech stated that the mid-term clinical data of the Cardiovalve tricuspid valve replacement system released at the PCR London Valves 2025 conference fully demonstrated the excellent clinical effectiveness of the product in the treatment of severe tricuspid regurgitation, and received high recognition from international clinical experts at the conference. The company will continue to actively promote the global clinical registration and development process of innovative products, including the Cardiovalve system.